Study Phase 3

Clinical Evaluation of Risperidone versus Haloperidol in Treatment Resistant Chronic Schizophrenic Patients

  • PDF icon for CSR Summary CSR Summary Not Yet Available
  • Globe symbol for NCT Number NCT Number Not Available
  • Notebook for Primary Citation Primary Citation Not Available
  • Spreadsheet for Data Specification Data Specification Not Available

Trial Information

Generic NameRisperidoneProduct NameRISPERDAL®Therapeutic AreaBehaviors and Mental DisordersEnrollment136% FemaleN/A% WhiteN/A
Product ClassAtypical AntipsychoticsSponsor Protocol NumberRIS-CAN-8Data PartnerJohnson & JohnsonCondition StudiedSchizophreniaMean/Median Age (Years)N/A

Supporting Documentation

  • Clinical Study Report Available
Additional Information

Please note: individual participant-level data are not available for this trial. Only the full clinical study report is available.

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.